12:00 AM
 | 
Dec 07, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AEG35156: Phase IIb started

Aegera began an open-label, international Phase IIb trial to evaluate cytarabine and idarubicin with or without 350 mg/m 2 intravenous AEG35156...

Read the full 81 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >